Myriad Genetics' Earnings Beat Sparks 35.67% After-Hours Rally

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Global Financial Markets Prepare for 2025 Global financial markets are gearing up for an important year ahead. As we approach 2025, significant changes in currency markets and commodity prices are predicted to present both challenges and opportunities for investors, traders, and market analysts. This article delves into five major themes expected to shape the financial...

Understanding Synovus Financial Inc's Current Stock Performance In today's market, Synovus Financial Inc. (NYSE: SNV) is priced at $45.89, reflecting a 1.30% rise. However, the recent history shows a decline, with the stock falling by 7.83% over the last month and 6.52% over the past year. This fluctuation raises questions among shareholders about the stock's potential...

Buffett's Recent Moves in the ETF Landscape Recently, Berkshire Hathaway made headlines as it divested from two key S&P 500 ETFs, including the Vanguard S&P 500 ETF, the largest of its kind globally. This bold decision has raised eyebrows in the investment community, leading many to ponder what insights this could offer into the mind of Warren Buffett, often revered as...

Sumsub and TELUS Digital: A Powerful Partnership In today's rapidly evolving digital landscape, securing the workforce has never been more critical. With companies expanding their reach globally, the need for streamlined processes in employee verification and onboarding has risen to the forefront. Sumsub, a renowned full-cycle verification platform, has joined forces with...

Palantir Expands PFCS Forward Authorization Palantir Technologies is making significant strides with its PFCS Forward, which has recently broadened its Provisional Authorizations for Impact Level 5 and Impact Level 6 to encompass both on-premises and edge deployments. This strategic move facilitates a more versatile implementation of its technology across numerous...